Wilmington Savings Fund Society FSB Makes New $2.19 Million Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Wilmington Savings Fund Society FSB acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 4,702 shares of the pharmaceutical company's stock, valued at approximately $2,187,000.

A number of other institutional investors have also recently bought and sold shares of VRTX. World Investment Advisors LLC bought a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth $24,280,000. Sanctuary Advisors LLC boosted its holdings in Vertex Pharmaceuticals by 46.1% during the third quarter. Sanctuary Advisors LLC now owns 42,903 shares of the pharmaceutical company's stock worth $19,348,000 after buying an additional 13,529 shares during the last quarter. Anchor Investment Management LLC boosted its holdings in Vertex Pharmaceuticals by 1,352.3% during the third quarter. Anchor Investment Management LLC now owns 1,583 shares of the pharmaceutical company's stock worth $736,000 after buying an additional 1,474 shares during the last quarter. Advisory Resource Group grew its position in shares of Vertex Pharmaceuticals by 3.2% during the 3rd quarter. Advisory Resource Group now owns 1,970 shares of the pharmaceutical company's stock worth $916,000 after buying an additional 61 shares during the period. Finally, Hohimer Wealth Management LLC increased its stake in shares of Vertex Pharmaceuticals by 3.1% in the 3rd quarter. Hohimer Wealth Management LLC now owns 2,320 shares of the pharmaceutical company's stock valued at $1,079,000 after acquiring an additional 70 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ:VRTX traded down $0.39 on Friday, hitting $463.73. The company had a trading volume of 1,097,110 shares, compared to its average volume of 1,269,808. The stock has a 50 day moving average price of $473.50 and a 200 day moving average price of $475.84. Vertex Pharmaceuticals Incorporated has a 1-year low of $391.01 and a 1-year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts' consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Vertex Pharmaceuticals's quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.67 EPS. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the topic of several recent analyst reports. Scotiabank lifted their price objective on shares of Vertex Pharmaceuticals from $480.00 to $486.00 and gave the stock a "sector perform" rating in a research note on Tuesday, November 5th. Bank of America decreased their price target on shares of Vertex Pharmaceuticals from $550.00 to $541.00 and set a "buy" rating for the company in a report on Monday, October 14th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $480.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Morgan Stanley lifted their target price on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an "equal weight" rating in a report on Tuesday, November 5th. Finally, Canaccord Genuity Group increased their price target on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a "sell" rating in a report on Wednesday, November 6th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $506.20.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.